President Trump’s critical comments on trade with China caused a market sell-off, with concerns over supply chain disruptions and increased costs for technology companies. Neogen’s stock, known for volatility, dropped significantly after China’s export controls on rare earth minerals. Despite a decline in revenue, Neogen’s earnings were in line with estimates, with a positive full-year outlook. The stock is down 49% this year but offers potential for long-term growth. Stay informed on stock movements by adding them to your watchlist for timely updates.

Read more at Barchart: Tandem Diabetes, agilon health, GoodRx, Neogen, and Fortrea Stocks Trade Down, What You Need To Know